焦点粘着
癌症研究
任天堂
化学
表皮生长因子受体
肿瘤微环境
细胞外基质
细胞生物学
表皮生长因子受体抑制剂
重编程
西妥昔单抗
靶向治疗
肺癌
磷酸化
信号转导
机械转化
癌症
癌症治疗
癌细胞
激酶
帕西林
整合素
奥西默替尼
受体
肿瘤进展
原癌基因酪氨酸蛋白激酶Src
作者
Keli An,Y F Li,Chunyu Cao,M Wang,Xiaohui Jia,Guorui Jin,Bo Cheng,Yuanbo Jia,Lei Wang,Guo H,Feng Xu,Kai Qu
出处
期刊:Neoplasia
[Elsevier BV]
日期:2026-06-16
卷期号:79: 101328-101328
被引量:3
标识
DOI:10.1016/j.neo.2026.101328
摘要
Mechanical abnormalities in the tumor microenvironment (TME), such as matrix stiffening and hypoxia, drive tumor invasion and therapy resistance. Yet targeting these cues with spatial precision remains challenging. Here we present a hypoxia-responsive dual-warhead PROTAC (hrFP-E) that couples focal adhesion kinase (FAK) degradation with inhibition of epidermal growth factor receptor (EGFR), introducing a mechano-chemical therapy paradigm. hrFP-E is equipped with a nitroreductase (NTR)-sensitive motif activated in hypoxic regions to release a FAK degrader (FP) and an EGFR inhibitor (Erlotinib). In lung cancer models, hrFP-E induces near-complete FAK depletion (∼96-99%) and substantial EGFR pathway suppression (∼88%), resulting in synergistic anti-migration and anti-proliferation effects in both 2D and 3D assays. Mechanistically, FAK degradation stabilizes large focal-adhesions, alters actomyosin contractility, elevates ROS, and reduces collagen deposition, collectively reprogramming the TME. In vivo, hrFP-E achieves ∼66% tumor growth inhibition without overt toxicity while reducing tissue stiffness and collagen density. This platform is inherently modular and compatible with alternative oncogenic drivers and disease-specific gates. Our work establishes mechano-chemical therapeutics, spatiotemporally controlled degraders that rewire tumor mechanics alongside growth signaling, as a generalizable strategy for solid tumor treatment.
科研通智能强力驱动
Strongly Powered by AbleSci AI